SPY441.40-4.34 -0.97%
DIA345.64-1.80 -0.52%
IXIC15,043.97-137.96 -0.91%

Novartis, NHS England Ink Access Deal For Cholesterol Drug Leqvio

Benzinga · 09/01/2021 06:23
  • The U.K. government, NHS England, and Novartis AG (NYSE:NVS) unveiled a "world-first" reimbursement deal for providing broader access to anti-cholesterol drug Leqvio (inclisiran) after the U.K.'s healthcare cost agency NICE approved the medicine.
  • The news follows the January 2020 announcement of the deal parameters. The partners are now ready to move into the "implementation phase."
  • After reviewing clinical data from three Phase 3 trials, England's NICE endorsed the drug in patients with a history of cardiovascular events and whose LDL-C concentrations are persistently 2.6 mmol/l or higher despite treatment with lipid-lowering medicines.
  • Over the next three years, NHS England expects to treat about 300,000 patients with the drug, which won its European nod last year as an add-on therapy for those patients whose cholesterol levels do not respond adequately to statins.